• Twist Bioscience (NasdaqGS:TWST) reported its twelfth consecutive quarter of revenue growth.
• The company raised its full year outlook, citing momentum in AI enabled DNA synthesis and wider use of its platform.
• Management also reiterated a focus on progressing toward profitability alongside scaling the business.

Twist Bioscience, a provider of synthetic DNA and related tools, operates at the intersection of biotechnology and AI driven research. Its platform supports customers in areas such as drug discovery, genomics, and data storage that rely heavily on accurate, high throughput DNA synthesis. With AI tools becoming more common in lab workflows, the company’s position in this niche has drawn attention from both industry users and investors.

For investors watching NasdaqGS:TWST, the combination of ongoing revenue growth, a higher full year outlook, and an explicit focus on profitability brings the business model into clearer focus. The key questions now center on how efficiently Twist can convert demand for AI enabled DNA synthesis into scale, margin improvement, and a more mature financial profile over time.

Stay updated on the most important news stories for Twist Bioscience by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Twist Bioscience.

Twist Bioscience’s twelfth straight quarter of revenue growth, with first quarter sales of US$103.7 million compared to US$88.71 million a year ago, and a raised full year outlook to US$435 million to US$440 million, signals that customer demand for AI enabled discovery and DNA tools is feeding through into the numbers. Guidance for second quarter revenue of US$107 million to US$108 million, around 16% year on year growth at the midpoint, points to continued traction even as the company still reports a net loss of US$30.51 million and only a small year on year improvement in basic loss per share.

How this earnings print fits the Twist Bioscience narrative

For investors who see Twist as a scaling DNA synthesis platform, the raised guidance and 17% year on year revenue growth in the quarter will likely be read as support for the more optimistic narrative around AI enabled drug discovery and protein solutions. At the same time, the continued losses and management’s goal of adjusted EBITDA breakeven by the fourth quarter of fiscal 2026 speak directly to the more cautious narrative that focuses on profitability timing, cost discipline, and competitive pressure from larger tools players such as Thermo Fisher Scientific, Illumina, and Agilent Technologies.

Key risks and rewards in focus

• Twelve consecutive quarters of revenue growth and full year guidance for roughly 16% growth at the midpoint suggest Twist is gaining traction with customers using its platform for AI powered discovery.
• Management’s reiterated aim for adjusted EBITDA breakeven by late fiscal 2026 gives investors a clearer yardstick to track progress toward profitability.
• The company is still reporting a quarterly net loss of US$30.51 million and remains unprofitable, while analysts have flagged profitability as a key risk over the next three years.
• Analysts have also highlighted customer concentration and competition from larger peers as ongoing risks that could affect revenue stability and future margins.

What to watch next

Looking ahead, the key signals to watch are whether Twist can keep quarterly revenue close to its guidance range, improve gross margin, and narrow losses while it invests in AI related opportunities and infrastructure. If you want a broader sense of how different investors are thinking about these trade offs, take a moment to check community narratives on the company’s dedicated page and compare the bullish and bearish cases against your own expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.